Verastem, Inc. (VSTM)

Market Cap	493.59M
Revenue (ttm)	2.14M
Net Income (ttm)	-166.56M
Shares Out	61.55M
EPS (ttm)	-3.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,463,013
Open	8.30
Previous Close	8.21
Day's Range	8.01 - 8.76
52-Week Range	2.24 - 9.10
Beta	0.83
Analysts	Strong Buy
Price Target	12.75 (+58.98%)
Earnings Date	Aug 7, 2025

About VSTM

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 27, 2012
• Employees: 78
• Stock Exchange: NASDAQ
• Ticker Symbol: VSTM
• Website: https://www.verastem.com

Analyst Forecast

According to 9 analysts, the average rating for VSTM stock is "Strong Buy." The 12-month stock price target is $12.75, which is an increase of 58.98% from the latest price.

Price Target

$12.75

(58.98% upside)

Analyst Consensus: Strong Buy